Last reviewed · How we verify
NCT04387929
Detection of Anti-COVID-19 Antibody Levels in an Hospital Population
trial testing Detection of anti-COVID-19 antibody level in COVID-19 in 6,000 participants. Status unknown.
30 May 2021
Quick facts
| Lead sponsor | Istituto Clinico Humanitas |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 6,000 |
| Start date | 4 May 2020 |
| Primary completion | 30 May 2021 |
| Estimated completion | 30 May 2021 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Detection of anti-COVID-19 antibody level
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Istituto Clinico Humanitas
Who can join
Adults 18 to 90, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 (SARS-CoV-2) infection in health professionals represent a significant criticality both for the risk of spreading the disease and for the organizational aspects that follow. The objective of the study is to evaluate the spread of COVID-19 virus within the hospital population of Humanitas through the monitoring of the levels of IgG antibodies. Moreover, viral load will be measured by RT-PCR in the subgroup positive to IgG antibodies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19.
Levi R, Azzolini E, Pozzi C, Ubaldi L, et al · · 2021 · cited 87× · PMID 33956667 · DOI 10.1172/jci149154 -
SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy.
Sandri MT, Azzolini E, Torri V, Carloni S, et al · · 2021 · cited 20× · PMID 34112899 · DOI 10.1038/s41598-021-91773-4 -
The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients.
Levi R, Ubaldi L, Pozzi C, Angelotti G, et al · · 2021 · cited 12× · PMID 35072166 · DOI 10.1038/s43856-021-00032-0 -
Antibody Titer Correlates with Omicron Infection in Vaccinated Healthcare Workers.
Mollura M, Sarti R, Levi R, Pozzi C, et al · · 2022 · cited 6× · PMID 36560609 · DOI 10.3390/v14122605 -
A cautionary note on recall vaccination in ex-COVID-19 subjects
Levi R, Azzolini E, Pozzi C, Ubaldi L, et al · · 2021 · cited 3× · DOI 10.1101/2021.02.01.21250923 -
Analyzing the diffusion and duration of antibodies to SARS-CoV-2 during the natural infection and comparison with vaccination.
Pozzi C, Azzolini E, Rescigno M. · · 2023 · cited 1× · PMID 36785809 · DOI 10.1140/epjp/s13360-023-03732-9 -
The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients
Levi R, Ubaldi L, Pozzi C, Angelotti G, et al · · 2021 · cited 1× · DOI 10.1101/2021.02.05.21251219 -
Adverse Events to Comirnaty Vaccine Are Linked to Sex, Age and BMI: Should We Consider Reducing the Dose for Females?
Azzolini E, Mollura M, Pozzi C, Ubaldi L, et al · · 2023 · PMID 36992089 · DOI 10.3390/vaccines11030505
Verify or expand the search:
- PubMed search for NCT04387929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Istituto Clinico Humanitas trials
Trials by the same sponsor.
- NCT06944288 — Microbiota as Early Diagnostic and predictivE Factor for Osteoarthritic Degeneration and Microbial Contamination · NA · not yet recruiting
- NCT07358247 — Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction · not yet recruiting
- NCT07362342 — RIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery · not yet recruiting
- NCT07346274 — Intra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. · enrolling by invitation
- NCT07491419 — The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04387929 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Clinico Humanitas
- Last refreshed: 15 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04387929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing